United Therapeutics' Remodulin limits 'procompetitive,' US appeals court says
United Therapeutics did not violate antitrust law by hindering Sandoz's access to cartridges for its generic competitor to UTC's brand-name hypertension treatment Remodulin, a US federal appeals court said Wednesday.United Therapeutics...To view the full article, register now.
Already a subscriber? Click here to view full article